By moving beyond naturally occurring antibody domains, we can generate new molecules to overcome a range of problems researchers using antibodies have been facing. The interaction of antibody constant domains with Fc-receptors may be advantageous for certain biotherapeutics, but also result in undesirable background staining in flow-cytometry.
Equally, murine constant domains can be cross-linked by anti-mouse antibodies found in some human sera, leading to false positives in sandwich ELISA-type diagnostic tests. Removal of the constant domain and addition of a proprietary dimerization domain to stabilize the otherwise unstable F(ab’)2 format results in a reagent with superior characteristics for diagnostic applications (AbFab2).
Finally, bispecific antibodies furthermore expand the repertoire of antibody formats and possibilities accessible to researchers through Absolute Antibody.